PCN221 Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy: Qualitative Analyses of Early Post-Treatment Interviews With Relapsed and Refractory Multiple Myeloma (RRMM) Patients in the KarMMa Clinical Trial

Category Primary study
JournalValue in Health
Year 2021
This article has no abstract
Epistemonikos ID: 25285a2c05fc1be3829c037a4eda90b02fdabbeb
First added on: Feb 12, 2025